Imatinib Cf

Imatinib, the active ingredient in Imatinib Cf, is a tyrosine kinase inhibitor presented as an oral pharmaceutical product for systemic use. It targets specific cancer cells and is employed in the treatment of certain hematologic and solid tumours, notably chronic myeloid leukemia and gastrointestinal stromal tumour.

GNH USA supplies Imatinib Cf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, providing quality‑assured products that meet European regulatory standards, through reliable logistics and dedicated support.

Imatinib acts on malignant cells driven by specific tyrosine kinase pathways, primarily BCR‑ABL, c‑KIT and PDGFR.

- Chronic myeloid leukemia: reduces disease burden by inhibiting BCR‑ABL driven proliferation. - Gastrointestinal stromal tumor: blocks c‑KIT signaling to shrink or control tumor growth. - Philadelphia chromosome‑positive acute lymphoblastic leukemia: suppresses leukemic cell expansion through BCR‑ABL inhibition.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Edema: fluid retention, often in the extremities. - Fatigue: persistent tiredness.

Serious or Rare Side Effects: - Neutropenia: dangerously low white‑blood‑cell count. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: reduced heart function, especially in patients with pre‑existing disease.

When prescribing Imatinib, clinicians should observe several safety measures to minimize risks.

- Monitor blood counts: perform regular CBC tests to detect neutropenia or anemia. - Assess liver function: schedule periodic liver‑enzyme evaluations for hepatotoxicity. - Evaluate cardiac status: check baseline and ongoing cardiac function in at‑risk patients. - Avoid use in known hypersensitivity: discontinue if allergic reactions occur. - Store at ambient temperature: keep tablets in original container, protect from moisture and light.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): raise imatinib levels, risk of toxicity. - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): lower imatinib levels, reduce efficacy. - Warfarin: may increase INR and bleeding risk.

Moderate Interactions (Monitor Closely): - Antacids (aluminum or magnesium): may reduce oral absorption, separate dosing recommended. - Diuretics (e.g., furosemide): can enhance electrolyte disturbances. - Live vaccines: immunogenicity may be reduced, assess benefit‑risk.